APR 18 2027
Teva Pharmaceutical Industries Ltd. — ecopipam $TEVA
for pediatric Tourette syndrome
About
Tourette syndrome is a neurological disorder characterized by involuntary movements and vocalizations called tics, which can be disruptive and difficult to control. Ecopipam is an oral drug that works by blocking a specific dopamine receptor in the brain, which is thought to be overactive in this condition. This targeted approach may help reduce the frequency and severity of tics in children and adolescents.
Pivotal trial
This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on ecopipam
- FDA accepts Teva's ecopipam NDA for pediatric Tourette syndrome - scanx.trade
- Ecopipam reduces relapse risk in pediatric Tourette syndrome - 2 Minute Medicine
- Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing - Yahoo Finance
- FDA Accepts Ecopipam NDA for Tourette Syndrome, Remlifanserin Receives Fast Track Designation for AD Psychosis, Alterity Reaches FDA Alignment on ATH434 - neurologylive.com
- TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome - Yahoo Finance
Sponsor Watch — recent news on Teva Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing
- TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome